Symbiotec Pharmalab plans a ₹150 crore IPO to repay debt and expand operations. The company holds a global leadership position in corticost...

Analysts recommend Hindustan Copper and Concord Biotech after both stocks broke key resistance levels with strong price action, volume and ...

Our technical analysts identify select stocks every trading day that may gain momentum even in volatile markets. Here are the technical cal...

Concord Biotech stock shows a breakout from a seven-month consolidation phase. Experts suggest buying the stock for a target above 1,500 le...

The Indian stock market rallied around 3% over the last week, recouping its early losses despite global volatility. Analysts expect the mar...

Concord Biotech's shares surged over 6% after receiving USFDA approval for its Tofacitinib Tablets in 5 mg and 10 mg strengths. This approv...

Concord Biotech shares saw a significant jump on Wednesday. This surge followed the company's announcement of receiving approval from the U...

Concord Biotech shares fell 16% to Rs 1,777.7 after the company reported a 2.1% YoY decline in Q3 FY25 net profit to Rs 75.92 crore, despit...

Concord Biotech is a biotechnology company and a leading maker of select fermentation-based APIs across immunosuppressants and oncology in ...

Concord Biotech is a biotechnology company and a leading maker of select fermentation-based APIs across immunosuppressants and oncology in ...

Analysts are of the opinion that a market premium of over 15% on the issue price is justified based on the company's business model, which ...

The issue of SBFC Finance comprises fresh equity issue of Rs 600 crore and an offer for sale (OFS) of Rs 425 crore, while Concord Biotech i...

Analysts advised investors to subscribe to Concord Biotech IPO given its complex product portfolio, presence in niche space, strong client ...

The initial public offering (IPO) of Concord Biotech will open for subscription on August 4. The issue closes on August 8. The company's sh...

According to the draft papers, Concord Biotech's IPO is entirely an offer for sale of (OFS) of 2,09,25,652 equity shares by Helix Investmen...

Sources told ET that the IPO would be of ₹2000 crore - ₹2500 crore size.The issue with a face value of ₹1 per equity share is a complete of...

As per an F&S report, Concord Biotech commands a market share of over 20 per cent by volume in 2021 across identified fermentation-based AP...